In vivo localization of a bispecific antibody which targets human T lymphocytes to lyse human colon cancer cells

Int J Cancer. 1989 Mar 15;43(3):501-7. doi: 10.1002/ijc.2910430327.


A bispecific MAb was derived from the fusion of a hybridoma producing MAb CD3 with a hybridoma producing MAb L-DI (which is directed against a 41-kDa glycoprotein expressed in most gastro-intestinal and pancreatic carcinomas). Bispecific antibody molecules were isolated from parental antibody molecules by the use of hydroxylapatite-HPLC and shown to target human cytolytic T lymphocytes, irrespective of their original specificity, to specifically lyse human colon carcinoma cells. Localization studies in vivo using nude mice bearing human colon carcinoma xenografts showed significant accumulation of the HPLC-purified 125I-labelled bispecific antibodies into the tumor compared to 131I-labelled control CD3 antibody.

MeSH terms

  • Animals
  • Antibodies, Neoplasm / analysis*
  • Antibodies, Neoplasm / biosynthesis
  • Antibodies, Neoplasm / immunology
  • Chromatography, High Pressure Liquid / methods
  • Colonic Neoplasms / immunology*
  • Flow Cytometry
  • Fluorescent Antibody Technique
  • Humans
  • Hybridomas / immunology
  • Mice
  • Mice, Nude
  • Neoplasm Transplantation
  • T-Lymphocytes, Cytotoxic / immunology*


  • Antibodies, Neoplasm